Gland Pharma Limited — Important, 04-11-2024: Financial Result Updates

Gland Pharma Limited reported its Q2 FY25 results, achieving a revenue of ₹14,058 million, up 2% year-over-year, with a PAT of ₹1,635 million, down 16%. The EBITDA margin decreased to 21% from 23% in the previous year. The base business (excluding Cenexi) saw a 5% revenue growth, while its EBITDA margin remained stable at 34%. Additionally, Ms. Wei Huang was appointed as a Non-Executive Director, and the Board was reconstituted during the meeting.